<?xml-stylesheet type='text/xsl' href='anzctrTransform.xsl'?>
<ANZCTR_Trial requestNumber="365016">
  <stage>Registered</stage>
  <submitdate>20/09/2013</submitdate>
  <approvaldate>8/10/2013</approvaldate>
  <actrnumber>ACTRN12613001121752</actrnumber>
  <trial_identification>
    <studytitle>Effect of Cabergoline on biochemical and anthropometric parameters of patient with Impaired Glucose metabolism (Impaired Fasting Glucose/Impaired Glucose Tolerance)</studytitle>
    <scientifictitle>Effect of Cabergoline Vs placebo on HbA1C, HOMA-IR, HOMA-Beta, FPG, anthropometric parameters in patient with Impaired fasting glucose/Impaired glucose tolerance.</scientifictitle>
    <utrn />
    <trialacronym />
    <secondaryid>Nill</secondaryid>
  </trial_identification>
  <conditions>
    <healthcondition>Prediabetes</healthcondition>
    <conditioncode>
      <conditioncode1>Metabolic and Endocrine</conditioncode1>
      <conditioncode2>Metabolic disorders</conditioncode2>
    </conditioncode>
  </conditions>
  <interventions>
    <interventions>addition of Cabergoline 0.5 mg oral tabletes twice weekly for 4 month or placebo in patients with prediabetes receiving a balanced diet, to to measure patient compliance to Cabergoline, tablet returned counted at the final visit, in addition to comparing thr prolactin level of every patient.</interventions>
    <comparator>Placebo contains lactose and other excipient of Cabergoline tabletes</comparator>
    <control>Placebo</control>
    <interventioncode>Treatment: Drugs</interventioncode>
  </interventions>
  <outcomes>
    <primaryOutcome>
      <outcome>reversal of insulin resistance based on HOMA-IR Model.
HOMA-IR will be calculated, using a fasting plasma sample, insulin level, and was derived by use of the insulin-glucose product, divided by a constant (405 when using mg/dL and 22.5 when using mmol/L for FPG reporting) </outcome>
      <timepoint>4 months</timepoint>
    </primaryOutcome>
    <primaryOutcome>
      <outcome>Improving Insulin secretion based on HOMA-Beta model.
HOMA-Beta will be calculated as HOMA-IR.</outcome>
      <timepoint>4 month</timepoint>
    </primaryOutcome>
    <secondaryOutcome>
      <outcome>alleviation of HbA1C level
HbA1C measured using enzymatic method and high-performance liquid chromatography (HPLC)</outcome>
      <timepoint>4 month</timepoint>
    </secondaryOutcome>
  </outcomes>
  <eligibility>
    <inclusivecriteria>Fasting Plasma Glucose (FPG): 100-110 mg/dL or/and 2 hour Plasma Glucose after Oral Glucose Tolerance Test (2hPG): 140-199 mg/dL.</inclusivecriteria>
    <inclusiveminage>20</inclusiveminage>
    <inclusiveminagetype>Years</inclusiveminagetype>
    <inclusivemaxage>65</inclusivemaxage>
    <inclusivemaxagetype>Years</inclusivemaxagetype>
    <inclusivegender>Both males and females</inclusivegender>
    <healthyvolunteer>No</healthyvolunteer>
    <exclusivecriteria>1) severe hepatic failure (Child-Pugh scores of 10 or higher)
2) history of pulmonary, pericardial, cardiac valvular, or retroperitoneal fibrotic disorders; increased risk of pleural effusion/pulmonary fibrosis 
3) hypersensitivity to ergot derivatives 
4) uncontrolled hypertension 
5) Diabetes
6) Pregnant Women
7) Lactating Women
8) Major psychiatric disorders
9) Recieving Medication effect prolactin secretion
10) Bulimia or/and anorexia nervosa</exclusivecriteria>
  </eligibility>
  <trial_design>
    <studytype>Interventional</studytype>
    <purpose>Treatment</purpose>
    <allocation>Randomised controlled trial</allocation>
    <concealment />
    <sequence />
    <masking>Blinded (masking used)</masking>
    <assignment>Parallel</assignment>
    <designfeatures />
    <endpoint>Efficacy</endpoint>
    <statisticalmethods />
    <masking1>True</masking1>
    <masking2>True</masking2>
    <masking3>True</masking3>
    <masking4>True</masking4>
    <patientregistry>False</patientregistry>
    <followup />
    <followuptype />
    <purposeobs />
    <duration />
    <selection />
    <timing />
  </trial_design>
  <recruitment>
    <phase>Phase 2</phase>
    <anticipatedstartdate>15/01/2013</anticipatedstartdate>
    <actualstartdate>1/07/2013</actualstartdate>
    <anticipatedenddate>30/10/2013</anticipatedenddate>
    <actualenddate />
    <samplesize>70</samplesize>
    <actualsamplesize />
    <recruitmentstatus>Recruiting</recruitmentstatus>
    <recruitmentcountry>,Outside</recruitmentcountry>
    <recruitmentstate />
    <countryoutsideaustralia>
      <country>Iran, Islamic Republic Of</country>
      <state>Tehran</state>
    </countryoutsideaustralia>
  </recruitment>
  <sponsorship>
    <primarysponsortype>University</primarysponsortype>
    <primarysponsorname>Shahid Beheshti University of Medical Sciences</primarysponsorname>
    <primarysponsoraddress>Velenjak, near Talighani hospital, 3rd street, Tehran,Tehran, Iran PO box: 14397-65461</primarysponsoraddress>
    <primarysponsorcountry>Iran, Islamic Republic Of</primarysponsorcountry>
    <fundingsource>
      <fundingtype>University</fundingtype>
      <fundingname>Shahid Beheshti University of Medical Sciences
</fundingname>
      <fundingaddress>Velenjak, near Talighani hospital, 3rd street, Tehran,Tehran, Iran PO box: 14397-65461</fundingaddress>
      <fundingcountry>Iran, Islamic Republic Of</fundingcountry>
    </fundingsource>
    <secondarysponsor>
      <sponsortype>None</sponsortype>
      <sponsorname />
      <sponsoraddress />
      <sponsorcountry />
    </secondarysponsor>
  </sponsorship>
  <ethicsAndSummary>
    <summary>Impaired Glucose metabolism has no treatment and only life style modification could stop progression of this condition to diabetes, so we want to try effect of cabergoline in this condition to alleviate metabolic impairment and progression to diabetes.</summary>
    <trialwebsite />
    <publication />
    <ethicsreview>Approved</ethicsreview>
    <publicnotes />
    <ethicscommitee>
      <ethicname>Ethics commiittee, Shahid Beheshti University of Medical sciences</ethicname>
      <ethicaddress>Velenjak, near Talighani hospital, 3rd street, Tehran,Tehran, Iran PO box: 14397-65462</ethicaddress>
      <ethicapprovaldate>1/03/2013</ethicapprovaldate>
      <hrec />
      <ethicsubmitdate>2/02/2013</ethicsubmitdate>
      <ethiccountry />
    </ethicscommitee>
  </ethicsAndSummary>
  <attachment />
  <contacts>
    <contact>
      <title>Dr</title>
      <name>Mohammad Abbasinazari</name>
      <address>Velenjak, near Talighani hospital, 3rd street, Tehran,Tehran, Iran, Shahid Beheshti University of Medical Sciences PO box: 14397-65461</address>
      <phone>+98 2188873704</phone>
      <fax />
      <email>farshadpharm@yahoo.com</email>
      <country>Iran, Islamic Republic Of</country>
      <type>Principal Investigator</type>
    </contact>
    <contact>
      <title>Dr</title>
      <name>Hadi Esmaily</name>
      <address>Velenjak, near Talighani hospital, 3rd street, Tehran,Tehran, Iran, Shahid Beheshti University of Medical Sciences PO box: 14397-65461</address>
      <phone>+98 2188873704</phone>
      <fax />
      <email>esmaily_hadi@yahoo.com</email>
      <country>Iran, Islamic Republic Of</country>
      <type>Public Queries</type>
    </contact>
    <contact>
      <title>Dr</title>
      <name>Hadi Esmaily</name>
      <address>Velenjak, near Talighani hospital, 3rd street, Tehran,Tehran, Iran, Shahid Beheshti University of Medical Sciences PO box: 14397-65461</address>
      <phone>+98 2188873704</phone>
      <fax />
      <email>esmaily_hadi@yahoo.com</email>
      <country>Iran, Islamic Republic Of</country>
      <type>Scientific Queries</type>
    </contact>
    <contact>
      <title>Dr</title>
      <name>Hadi Esmaily</name>
      <address>Velenjak, near Talighani hospital, 3rd street, Tehran,Tehran, Iran, Shahid Beheshti University of Medical Sciences PO box: 14397-65461</address>
      <phone>+98 2188873704</phone>
      <fax />
      <email>esmaily_hadi@yahoo.com</email>
      <country>Iran, Islamic Republic Of</country>
      <type>Updating Information</type>
    </contact>
  </contacts>
</ANZCTR_Trial>